Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orthofix MedicalOFIX -2.00%57 EV-to-EBITDA is 27.94 as of Aug. 21, 2026, which is 68% above its 10-year median of 16.66. GuruFocus rates OFIX with a GF Score™ of 57/100 and a GF Value™ of $13.93 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 516 Medical Devices & Instruments companies, Orthofix Medical ranks worse than 77.52% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Orthofix Medical's enterprise value is $530.4 Mil.
Orthofix Medical's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $19.0 Mil. Therefore, Orthofix Medical's EV-to-EBITDA for today is 27.94.
The historical rank and industry rank for Orthofix Medical's EV-to-EBITDA or its related term are showing as below:
OFIX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -159.72 Med: 16.66 Max: 200.56
Current: 27.94
During the past 13 years, the highest EV-to-EBITDA of Orthofix Medical was 200.56. The lowest was -159.72. And the median was 16.66.
OFIX's EV-to-EBITDA is ranked worse than 77.52% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 14.7
vs OFIX: 27.94
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Orthofix Medical (NAS:OFIX) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Orthofix Medical's PE Ratio (TTM) for today is calculated as:
Orthofix Medical's share price for today is $9.81.
Orthofix Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.540.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Orthofix Medical's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Orthofix Medical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orthofix Medical EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Orthofix Medical's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Orthofix Medical's EV-to-EBITDA falls into.
Orthofix Medical's current Enterprise Value is $530.4 Mil.
Orthofix Medical's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orthofix Medical (OFIX) has a EV-to-EBITDA of 27.94 as of Aug. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Orthofix Medical. This is 68% above median its historical median of 16.66. According to the industry distribution chart, Orthofix Medical ranks #400 out of 516 companies in the Medical Devices & Instruments industry, placing it in the top 77.5%.
Is Orthofix Medical's EV-to-EBITDA too high?
Orthofix Medical's current EV-to-EBITDA of 27.94 is 68% above median its 10-year median of 16.66. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.70. Orthofix Medical's value of 27.94 is 90.1% above this industry median. Based on the distribution chart, Orthofix Medical ranks #400 out of 516 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Orthofix Medical has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orthofix Medical's EV-to-EBITDA compare to VMD and VREX?
According to the Medical Devices & Instruments industry distribution chart, Orthofix Medical ranks #400 out of 516 companies for EV-to-EBITDA. This places Orthofix Medical in the lower half of its industry. The industry median EV-to-EBITDA is 14.70. Orthofix Medical's value of 27.94 is 90.1% above this benchmark. While the company's 10-year median is 16.66 vs. the industry median of 14.70, Orthofix Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.70, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orthofix Medical's current EV-to-EBITDA of 27.94 is 90.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Orthofix Medical. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orthofix Medical's current EV-to-EBITDA is 27.94, which is 68% above median its own 10-year median of 16.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orthofix Medical stock overvalued right now?
Based on GuruFocus' analysis, Orthofix Medical (OFIX) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.93, compared to a current price of $9.81 — trading 29.6% below its estimated fair value. The current EV-to-EBITDA is 27.94, which is 68% above median its 10-year median of 16.66 and 90.1% above the Medical Devices & Instruments industry median of 14.70. Orthofix Medical's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Orthofix Medical (OFIX), the current EV-to-EBITDA is 27.94 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orthofix Medical (OFIX) Overvalued in 2026?
Based on GuruFocus' analysis, Orthofix Medical stock appears to be undervalued.
The current stock price of $9.81 is trading 29.6% below its estimated GF Value™ of $13.93.
GuruFocus considers Orthofix Medical to be Modestly Undervalued.
Key valuation signals for OFIX:
EV-to-EBITDA: 27.94 (68% above median its 10-year median of 16.66)
GF Value™: $13.93 vs. price of $9.81 (29.6% below fair value)
Industry Position: 90.1% above the Medical Devices & Instruments median (#400 of 516)
No single metric tells the full story. See the OFIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
57GF Score
Get the complete analysis for OFIX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OFIX has been successfully added to your 
